GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto A/S (OCSE:BIOPOR) » Definitions » EV-to-Revenue

Bioporto A/S (OCSE:BIOPOR) EV-to-Revenue : 22.04 (As of Jun. 20, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Bioporto A/S EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bioporto A/S's enterprise value is kr713.73 Mil. Bioporto A/S's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr32.38 Mil. Therefore, Bioporto A/S's EV-to-Revenue for today is 22.04.

The historical rank and industry rank for Bioporto A/S's EV-to-Revenue or its related term are showing as below:

OCSE:BIOPOR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.52   Med: 16.34   Max: 57.36
Current: 22.05

During the past 13 years, the highest EV-to-Revenue of Bioporto A/S was 57.36. The lowest was 1.52. And the median was 16.34.

OCSE:BIOPOR's EV-to-Revenue is ranked worse than
89.59% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.06 vs OCSE:BIOPOR: 22.05

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-20), Bioporto A/S's stock price is kr1.982. Bioporto A/S's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.09. Therefore, Bioporto A/S's PS Ratio for today is 22.52.


Bioporto A/S EV-to-Revenue Historical Data

The historical data trend for Bioporto A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto A/S EV-to-Revenue Chart

Bioporto A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.71 42.22 25.93 24.29 23.72

Bioporto A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.63 12.94 16.14 23.72 14.14

Competitive Comparison of Bioporto A/S's EV-to-Revenue

For the Diagnostics & Research subindustry, Bioporto A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto A/S's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bioporto A/S's EV-to-Revenue falls into.



Bioporto A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Bioporto A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=713.727/32.378
=22.04

Bioporto A/S's current Enterprise Value is kr713.73 Mil.
Bioporto A/S's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr32.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto A/S  (OCSE:BIOPOR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Bioporto A/S's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.982/0.088
=22.52

Bioporto A/S's share price for today is kr1.982.
Bioporto A/S's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bioporto A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioporto A/S (OCSE:BIOPOR) Business Description

Traded in Other Exchanges
Address
Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto A/S is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto A/S (OCSE:BIOPOR) Headlines

No Headlines